The term "me-too drug" or "follow-on drug" refers to a medication that is similar to a pre-existing drug, usually by making minor modifications to the prototype, reflected in slight changes in the profiles of side effects or activity, and used to treat conditions for which drugs already exist. While pharmaceutical companies have justified the development of me-toos as offering incremental improvements in efficacy, side-effects, compliance and cost, critics have questioned the increasing marketing of me-toos, their absorption of research and development resources and their impact on the innovation of new treatments.
| Property |
Value |
| dbo:abstract |
The term "me-too drug" or "follow-on drug" refers to a medication that is similar to a pre-existing drug, usually by making minor modifications to the prototype, reflected in slight changes in the profiles of side effects or activity, and used to treat conditions for which drugs already exist. While pharmaceutical companies have justified the development of me-toos as offering incremental improvements in efficacy, side-effects, compliance and cost, critics have questioned the increasing marketing of me-toos, their absorption of research and development resources and their impact on the innovation of new treatments. In 1956, Louis S. Goodman, co‐editor of Goodman and Gilman, referred to “the problem of the introduction of ‘me too’ drugs, that is, drugs without signal advantage of any sort”. However, me-too drugs can be novel compounds themselves. They are commonly used and include several beta blockers, antidepressants and stomach acid reducing and cholesterol lowering drugs. (en) |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Louise_Goodman_Yale.jpg?width=300 |
| dbo:wikiPageID |
46363582 (xsd:integer) |
| dbo:wikiPageLength |
16487 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1085054859 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Captopril dbr:Practolol dbr:Pravastatin dbr:Prilosec dbr:Propranolol dbr:Proton-pump_inhibitor dbr:Proton_pump_inhibitors dbr:Prozac dbr:Rosuvastatin dbr:Benzodiazepines dbr:Beta_blockers dbr:Bisoprolol dbr:Paxil dbr:Pfizer dbr:Research_and_development dbr:Active_(pharmacology) dbr:Chemical_similarity dbr:Generic_drug dbr:Enalapril dbr:Milton_Silverman dbr:Antibiotics dbr:Antidepressants dbr:Antihistamines dbr:Lexapro dbr:Louis_Lasagna dbr:Louis_S._Goodman dbr:Lovastatin dbr:Simvastatin dbr:Statins dbr:Zoloft dbr:Bristol-Myers_Squibb dbr:Sulfonamide_(medicine) dbc:Drugs dbr:Celexa dbr:Tranquillisers dbr:Ace_inhibitor dbr:Acebutolol dbr:Amitriptyline dbr:Doxepin dbr:Esketamine dbr:Esomeprazole dbr:Estes_Kefauver dbr:Fluvastatin dbr:Food_and_Drug_Administration dbr:Nortriptyline dbr:Novartis dbr:Oxford_English_Dictionary dbr:Goodman_&_Gilman's_The_Pharmacological_Basis_of_Therapeutics dbr:Prototype_drug dbr:International_Policy_Network dbr:James_Black_(pharmacologist) dbr:AstraZeneca dbr:Atorvastatin dbc:Pharmaceutical_industry dbc:Medical_terminology dbr:Labetalol dbr:Biosimilar dbr:Tagamet dbr:Diazepam dbr:Dosulepin dbr:Philip_R._Lee dbr:Pitavastatin dbr:Sotalol dbr:Imipramine dbr:Imperial_Chemical_Industries dbr:Metoprolol dbr:Nexium dbr:Axid dbr:Ranitidine dbr:Side_effect dbr:Unique_selling_proposition dbr:Pepcid dbr:Pharmaceutical_marketing dbr:Selective_serotonin_reuptake_inhibitors dbr:Desmond_Laurence dbr:Desmond_Laurence's_Clinical_Pharmacology dbr:File:Louise_Goodman_Yale.jpg |
| dbp:wikiPageUsesTemplate |
dbt:Reflist |
| dct:subject |
dbc:Drugs dbc:Pharmaceutical_industry dbc:Medical_terminology |
| rdfs:comment |
The term "me-too drug" or "follow-on drug" refers to a medication that is similar to a pre-existing drug, usually by making minor modifications to the prototype, reflected in slight changes in the profiles of side effects or activity, and used to treat conditions for which drugs already exist. While pharmaceutical companies have justified the development of me-toos as offering incremental improvements in efficacy, side-effects, compliance and cost, critics have questioned the increasing marketing of me-toos, their absorption of research and development resources and their impact on the innovation of new treatments. (en) |
| rdfs:label |
Me-too drug (en) |
| owl:sameAs |
wikidata:Me-too drug https://global.dbpedia.org/id/t1vt |
| prov:wasDerivedFrom |
wikipedia-en:Me-too_drug?oldid=1085054859&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Louise_Goodman_Yale.jpg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Me-too_drug |
| is dbo:wikiPageRedirects of |
dbr:Me-too_compound dbr:Me-Too dbr:Me_too_drug |
| is dbo:wikiPageWikiLink of |
dbr:Me-too_compound dbr:Clomipramine dbr:Me-Too dbr:Me_too_drug dbr:Me_Too |
| is foaf:primaryTopic of |
wikipedia-en:Me-too_drug |
